Aqueous two-phase systems enable multiplexing of homogeneous immunoassays

Aqueous two-phase systems enable multiplexing of homogeneous immunoassays
Multiphase polymer systems are used to confine unique antibody-conjugated beads that bind with high sensitivity and specificity to plasma protein biomarkers, eliciting amplified luminescent signals. The signal intensity from the beads is proportional to the levels of disease biomarkers in the blood plasma. If protein levels exceed the clinical threshold, the patients are identified as having the disease. Credit: Technology

A new protein biomarker test platform developed by researchers at the University of Michigan and Indiana University promises to improve diagnostic testing. The test can accurately and simultaneously measure multiple proteins that indicate the presence of diseases like graft-versus-host disease (bone marrow transplant rejection) in only two hours, no washing steps, and using only a minute volume of blood plasma. A report on this new technology can be found online in the journal Technology.

The protein test uses a micropatterning method developed in Shuichi Takayama's Micro/Nano/Molecular Biotechnology Lab. "Just as oil and water remain immiscible, we use two aqueous solutions that do not mix with each other," said Dr. Takayama, Professor of Biomedical Engineering and Macromolecular Science and Engineering. "Interestingly, these solutions can be patterned into arrays, whereas standard no-wash protein test reagents normally just mix together in solution. This novel capability makes it possible, for the first time, to measure multiple diagnostic proteins at a time in a no-wash format test."

To perform the assay, a few microliters of blood plasma is mixed with poly(ethylene glycol) and added to a microwell in a custom 384-well microplate. Next, microdroplets of dextran, containing complimentary pairs of antibody-beads, are dispensed into microbasins within the sample well. During a two-hour incubation, target plasma protein biomarkers diffuse from the poly() phase to the dextran droplets and become sandwiched by the antibody beads. The microplate is then read on a commercially available plate reader.

The team demonstrated the effectiveness of their bioassay by measuring biomarkers from cytokine-stimulated cells, as well as from the plasma of transplant patients. Detecting levels of proinflammatory cytokines and chemokines in can be crucial in the diagnosis of (GVHD) - the leading cause of death among allogeneic patients.

"We envision that our user-friendly and highly accurate platform will be widely used by academic and clinical researchers for diagnostics as well as other applications," said Arlyne Simon, Ph.D., the lead author on this publication. "To ease the adoption of our technology into research and clinical labs, we designed custom microplates that can be analyzed by commercially available plate readers."

More information: Arlyne B. Simon et al, Technology 02, 176 (2014). DOI: 10.1142/S2339547814500150

add to favorites email to friend print save as pdf

Related Stories

Better matching benefits bone marrow recipients

Jun 05, 2014

A new test for genetic matching in bone marrow transplantation developed by a West Australian specialist is showing dramatic improvements in transplant survival rates according to a Brazilian study.

Recommended for you

Testing time for stem cells

1 hour ago

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

20 hours ago

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments